Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

82 trials with published results (16%)

Research Maturity

311 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.7%

39 terminated out of 504 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

33%

167 trials in Phase 3/4

Results Transparency

26%

82 of 311 completed with results

Key Signals

82 with results89% success39 terminated

Data Visualizations

Phase Distribution

377Total
Not Applicable (106)
Early P 1 (1)
P 1 (31)
P 2 (72)
P 3 (53)
P 4 (114)

Trial Status

Completed311
Unknown76
Terminated39
Recruiting33
Withdrawn16
Not Yet Recruiting15

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 311 completed trials

Clinical Trials (504)

Showing 20 of 20 trials
NCT00811915Phase 3TerminatedPrimary

Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

NCT02711202Not ApplicableCompletedPrimary

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

NCT05879302Not ApplicableCompleted

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT02421497Not Yet Recruiting

MRI Technical Development and Applications in Kidney Disease

NCT04128189Phase 3Recruiting

Shingrix in Renal Transplant Recipients

NCT06744647Phase 2Recruiting

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06878560Phase 1Recruiting

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT03663335Phase 2CompletedPrimary

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT06568549Phase 4RecruitingPrimary

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

NCT05013112Not ApplicableCompletedPrimary

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

NCT06365437Phase 2TerminatedPrimary

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

NCT04870437Not ApplicableRecruitingPrimary

Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.

NCT07446296Not ApplicableNot Yet Recruiting

Kidney Transplant Improvement Through New Exercise Training to Increase Capacity

NCT00619528Not ApplicableCompleted

HLA-Identical Sibling Renal Transplant Tolerance

NCT06552169Phase 2RecruitingPrimary

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT05193565Phase 4Active Not RecruitingPrimary

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

NCT03504241Phase 1CompletedPrimary

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT04803058Phase 2Active Not RecruitingPrimary

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

NCT04803006Phase 2TerminatedPrimary

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

NCT07379957Not Yet RecruitingPrimary

Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

Scroll to load more

Research Network

Activity Timeline